Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

iodine I 124 omburtamab

A radioimmunoconjugate consisting of the iodine I 124-radiolabeled murine IgG1 monoclonal antibody omburtamab directed against the cell surface glycoprotein CD276 (4Ig-B7-H3) with potential for radioimaging using positron emission tomography (PET). Through convection enhanced delivery of iodine I 124 omburtamab, the antibody moiety binds to the 4Ig domain of CD276, and in turn CD276-expressing tumor cells may be visualized upon PET imaging of the iodine I 124 moiety. CD276, a tumor-associated antigen (TAA) and member of the B7 family of co-stimulatory proteins, suppresses natural killer (NK) cell and cytotoxic T-lymphocyte activation; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and its expression is associated with increased aggressiveness, poor prognosis and resistance.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:iodine I 124 MOAB 8H9
Abbreviation:124I-8H9
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search